SOPHiA GENETICS SA - Ordinary Shares (SOPH)

Liquid biopsy volumes doubled while U.S. market revenue surged 41% year over year.

SOPHiA GENETICS (NASDAQ:SOPH) reported third-quarter 2026 revenue growth of 25% year over year, supported by expansion in the U.S., growing adoption of liquid biopsy testing and contributions from biopharma collaborations. The company also narrowed its adjusted EBITDA loss and said it expects full-y

Canada Goose, Capital Clean Energy Carriers and SOPHiA Genetics have each seen unusual trading volume recently, driven by tariffs, LNG demand, and a strong earnings beat, respectively.

Revenue jumped 27% as platform volume surged and biopharma partnerships accelerated.

SOPHiA GENETICS (NASDAQ:SOPH) reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements. Revenue for the second quarter totaled $23.3 millio

SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript

SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript

SOPHiA GENETICS Q3 2025 results beat revenue estimates and the company raised its full-year 2025 outlook, driving positive investor sentiment.

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields

SOPHiA GENETICS beats Q2 2025 estimates with $18.32M revenue and $0.33 EPS, driving shares up 5.45% in pre-market trading.

SOPH stock results show that Sophia Genetics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

CoreWeave, a company backed by Nvidia, is preparing to go public in 2025.